

Risk factors for resistant bacterial colonisation in 24 European neonatal units in the NeoIPC project

Aislinn Cook¹, Matilda Berkell², Surbhi Malhotra-Kumar², Julia Bielicki^{1,3} on behalf of the NeoIPC Consortium

Background

- Infants on neonatal units are at risk of severe bacterial infections, particularly those born at <32 weeks
- Infants colonised by resistant bacteria have an increased risk of sepsis
- Most studies look at individual risk factors for infants being colonised during their hospital stay
- Understanding how individual AND neonatal unit-level risk factors contribute to risk of infants being colonised is important
- Allows us to inform infection prevention and control (IPC) strategies focusing on both direct and indirect effects of IPC on high-risk infants

Methods

- 24 sites in 8 countries conducted 4 cross-sectional surveys in a one-month period
- At each survey clinical data, stool samples were collected from all infants present on the unit
- Stool samples were analysed by PCR for the presence of bacterial resistance genes
- Colonised defined as detection of at least one gene of interest in stool
- Bayesian logistic regression model to assess individual and unit risk factors associated with resistant bacterial colonisation

Gene targets of interest in stool samples

- Carbapenem resistance: *blaKPC*, *blaNDM*, *blaVIM*, *blaIMP*, *blaOXA-48*
- Extended-spectrum beta-lactamase: *blaCTX-M group1*, *blaCTX-M group9*
- Vancomycin resistance: *vana*, *vanB*

Results




Figure: Number of infants colonised by antibiotic resistant bacteria (stool) per survey split by high risk (born <32 weeks gestation) and not high risk (born ≥32 weeks gestation) and total number of infants (not colonised) present on the day of the survey.

Overall


- 943 infants contributed data for 1846 infant-survey observations
- 1447/1846 (78%) possible stool samples collected
- Resistant bacterial colonisation was moderate overall (20%, 301/1447 samples)
- Significant variation between units and countries ($p < 0.001$) (Figure)

Characteristic	Resistant bacterial colonization status (stool samples)	
	Not colonised N = 1,050	Colonised N = 302
Country		
Switzerland	210 (20%)	2 (0.7%)
Germany	89 (8.5%)	7 (2.3%)
Estonia	33 (3.1%)	0 (0%)
Greece	180 (17%)	158 (52%)
Italy	50 (4.8%)	19 (6.3%)
Poland	75 (7.1%)	22 (7.3%)
Spain	175 (17%)	69 (23%)
United Kingdom	238 (23%)	25 (8.3%)
Gestational age (weeks)	32 (28 - 37)	33 (30 - 37)
Birthweight (grams)	1,715 (975 - 2,830)	1,820 (1,300 - 2,600)
Postnatal age (days) at survey	19 (7 - 42)	23 (10 - 51)
Length of stay on NICU at survey (days)	14 (5 - 31)	16 (7 - 39)
Surgery prior to survey	223 (21%)	56 (19%)
Skin-to-skin contact (KC) in prior 24 hours to survey	655 (62%)	131 (43%)
Presence of central line within 24 hours	224 (21%)	41 (14%)
Receipt of TPN in prior 24 hours	217 (21%)	40 (13%)
Antibiotic exposure within 14 days	578 (55%)	156 (52%)
Total patients on the unit	23 (17 - 32)	20 (15 - 25)
Proportion of infants colonised on unit	0.11 (0.00 - 0.24)	0.44 (0.25 - 0.71)
Proportion of infants on unit that are high risk (>32 weeks)	0.44 (0.36 - 0.58)	0.38 (0.30 - 0.53)

¹n (%); Median (Q1 - Q3); Country % is column percentage

Model Summary

- 781 infants with 1352 infant-survey observations had complete data for model (Table)
- Substantial variation in log-odds of colonisation
 - Between sites (log-odds 2.6, 95%CI: 1.7 - 3.9)
 - Between infants within sites (log-odds 2.0, 95% CI: 1.5 - 2.6)
- Receipt of TPN was associated with lower odds of colonisation
- Higher colonisation pressure on the unit was associated with increased odds of individual colonisation
- Lack of evidence that other clinical predictors associated with odds of colonisation



Conclusion

- Both low- and high-risk infants were colonised
- Colonisation pressure on neonatal unit is a risk factor for individual colonisation
- Unit-level IPC interventions target both direct and indirect effects of colonisation regardless of risk status
- Interventions focusing only on infants at high risk of sepsis will miss significant resistant bacterial colonisation in low-risk infants

The NeoDeco trial is a cluster-randomised hybrid implementation-effectiveness trial looking at the impact of implementing optimal kangaroo care on neonatal sepsis and resistant bacterial colonisation prevalence

1. Centre for Neonatal and Paediatric Infection, St. George's University of London, London, UK
 2. Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
 3. Paediatric Research Centre, University of Basel Children's Hospital, Basel, Switzerland



The NeoIPC Feasibility Study is sponsored by Fondazione Penta ETS

Learn more about the NeoIPC Project



The NeoIPC project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 965328

